中国新发传染病医学对策研发情况,1990-2022年
该研究考察了中国1990-2022年新发传染病医学对策的研发状况,发现研发管线多样且能快速响应疫情和政策变化,但前瞻性高创新候选产品有限,大部分疫苗和药物停滞在早期开发阶段。作者认为亟需转向先发制人的研发议程、持续投资、创新技术开发和加速研究转化。
要点
- 中国新发传染病医学对策研发管线多样且能快速响应疫情和政策变化。
- 前瞻性高创新候选产品有限,大部分疫苗和药物停滞在早期开发阶段。
- 作者认为亟需先发制人的研发议程、持续投资、创新技术开发和加速研究转化。
核心结论
- 中国新发传染病医学对策研发管线多样且能快速响应疫情和政策变化,但前瞻性高创新候选产品有限,大部分疫苗和药物停滞在早期开发阶段。
- 作者认为亟需转向先发制人的研发议程、持续投资、创新技术开发和加速研究转化,以应对下一次大流行。
研究设计与样本
- 该研究考察了中国1990-2022年新发传染病医学对策的研发现状。
主要发现
- 中国新发传染病医学对策研发管线多样且能快速响应疫情和政策变化。
- 前瞻性高创新候选产品有限,大部分疫苗和药物停滞在早期开发阶段。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the severe acute respiratory syndrome outbreak in 2003, China has invested substantial efforts in promoting scientific and technological advances for medical countermeasures against high-threat pathogens. The examination of China's landscape identifies progress and gaps in research and development (R&D) and also highlights management and regulatory issues that should be of concern to other countries. Our study examined the current state of R&D of medical countermeasures in China during 1990-2022. The findings showed a robust and diversified pipeline responding quickly to disease outbreaks and policy changes. However, proactive and highly innovative candidates are limited, and a large proportion of vaccines and drugs stagnate at the early development stage. A paradigm shift involving a preemptive R&D agenda and persistent investment, innovative technology development, and accelerated research translation is urgently needed to prepare for the next pandemic.
引用
- Ma J, Yang Y, Huang Y, et al. Research and Development of Medical Countermeasures for Emerging Infectious Diseases, China, 1990-2022. Emerg Infect Dis. 2025. PMID: 39714280. doi:10.3201/eid3101.230638
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。